Breast Cancer Clinical Trials

Showing 21-40 of 5,597 trials

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more

Day One Biopharmaceuticals, Inc.57 participantsStarted Jan 2023

Los Angeles, California, United States • Los Angeles, California, United States • Stanford, California, United States +11 more locations

RECRUITINGPhase 1

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

NCT04521764

This phase I trial investigates the side effects and best dose of using a modified measles virus, MV-s-NAP, in treating patients with invasive breast cancer that has spread to other places in the body (metastatic). Both the unmodified vaccination measles virus (MV-Edm) and this modified virus (MV-s-NAP) have been shown to multiply in and destroy breast cancer cells in the test tube and in research mice. MV-s-NAP has been altered by having an extra gene (piece of deoxyribonucleic acid \[DNA\]) so that virus can make a protein called helicobacter pylori neutrophil activating protein (NAP) which is normally expressed in inflammatory reactions. Monitoring blood, urine, tissue, and throat swab samples, and using imaging tests may help to determine whether MV-s-NAP has any impact on the amount of disease present in metastatic breast cancer patients.

Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaMetastatic Breast Adenocarcinoma+2 more

Mayo Clinic54 participantsStarted Sep 2020

Rochester, Minnesota, United States

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

Related Searches

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients

Cachexia and Gut Microbiota in Patients With Breast Cancer Receiving Home Care

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study

A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae

PALbociclib CoLlaborative Adjuvant Study

18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer

MammoVerse: Clinicians Focus Group

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Effect of Yoga Program on Quality of Life in Women With Breast Cancer Receiving Endocrine Therapy

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Magnetic Resonance Imaging in Radiotherapy for Breast Cancer